Back to top
more

Precigen (PGEN)

(Delayed Data from NSDQ)

$1.41 USD

1.41
409,867

+0.01 (0.71%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $1.41 0.00 (0.00%) 6:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Should You Buy Precigen, Inc. (PGEN) After Golden Cross?

by Zacks Equity Research

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Tango Therapeutics, Inc. (TNGX) delivered earnings and revenue surprises of 34.29% and 108.54%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Fulcrum Therapeutics, Inc. (FULC) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 13.64% and 45.10%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Paratek Pharmaceuticals (PRTK) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Paratek (PRTK) delivered earnings and revenue surprises of 7.89% and 1.23%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Heska (HSKA) Q1 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Heska (HSKA) delivered earnings and revenue surprises of -46.88% and 7.10%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Insmed (INSM) delivered earnings and revenue surprises of -8.33% and 1.29%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Here's Why Precigen, Inc. (PGEN) Is a Great 'Buy the Bottom' Stock Now

by Zacks Equity Research

Precigen, Inc. (PGEN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Fate Therapeutics (FATE) delivered earnings and revenue surprises of 32.56% and 124.91%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

BioMarin Pharmaceutical (BMRN) Q4 Earnings Lag Estimates

by Zacks Equity Research

BioMarin (BMRN) delivered earnings and revenue surprises of -7.69% and 0.69%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ultragenyx (RARE) delivered earnings and revenue surprises of -6.40% and 0.27%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Precigen, Inc. (PGEN) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Precigen, Inc. (PGEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Precigen, Inc. (PGEN) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Precigen, Inc. (PGEN) delivered earnings and revenue surprises of -140% and 67.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 30% and 0.48%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Precigen, Inc. (PGEN) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Precigen, Inc. (PGEN) delivered earnings and revenue surprises of 18.75% and 83.41%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

NeoGenomics (NEO) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

NeoGenomics (NEO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Precigen, Inc. (PGEN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Precigen, Inc. (PGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Precigen, Inc. (PGEN) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Precigen, Inc. (PGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Apellis Pharmaceuticals, Inc. (APLS) Moves 16.3% Higher: Will This Strength Last?

by Zacks Equity Research

Apellis Pharmaceuticals, Inc. (APLS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Precigen, Inc. (PGEN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Precigen, Inc. (PGEN) delivered earnings and revenue surprises of 28.57% and 53.21%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Allogene Therapeutics (ALLO) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 5.08% and 39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Precigen, Inc. (PGEN) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Precigen, Inc. (PGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Precigen (PGEN) Up on FDA Fast Track Tag for CAR-T Candidate

by Zacks Equity Research

Precigen (PGEN) is developing CAR T therapy candidate, PRGN-3006 UltraCAR-T, for treating acute myeloid leukemia in a phase I study. The FDA grants Fast Track designation.

Precigen, Inc. (PGEN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Precigen, Inc. (PGEN) delivered earnings and revenue surprises of 7.14% and 14.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Codexis (CDXS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Codexis (CDXS) delivered earnings and revenue surprises of 11.11% and 1.73%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Here's Why Precigen, Inc. (PGEN) Could be Great Choice for a Bottom Fisher

by Zacks Equity Research

Precigen, Inc. (PGEN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.